Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip World Congress & 3D-Printing

Michael Shuler's Biography



Michael Shuler, Samuel B. Eckert Professor of Engineering, Cornell University, President & CEO, Hesperos, Inc.

Michael L. Shuler is the Samuel B. Eckert Professor of Engineering in the Meing Department of Biomedical Engineering and in the School of Chemical and Biomolecular Engineering at Cornell University. Shuler has degrees in chemical engineering (BS, Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is CEO and President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science and is a fellow of numerous professional societies.

Michael Shuler Image

Can Multi-Organ Chips Be Used for Drug Development Studies?

Wednesday, 8 July 2015 at 10:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Effective human surrogates, created from combining human tissue engineered constructs with microfabricated systems, could have a major impact on drug development, particularly in making better decisions on which drugs to take into human clinical trials. Early prediction of human response would be crucial to such decisions. Our designs are guided by physiologically based pharmacokinetic models. We will describe possible approaches to use “pumpless”, low cost platforms to build such human surrogates for evaluation of potential response to drugs.

Can Multi-Organ Chips Be Used for Drug Development Studies?

Wednesday, 8 July 2015 at 10:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Effective human surrogates, created from combining human tissue engineered constructs with microfabricated systems, could have a major impact on drug development, particularly in making better decisions on which drugs to take into human clinical trials. Early prediction of human response would be crucial to such decisions. Our designs are guided by physiologically based pharmacokinetic models. We will describe possible approaches to use “pumpless”, low cost platforms to build such human surrogates for evaluation of potential response to drugs.


Add to Calendar ▼2015-07-08 00:00:002015-07-09 00:00:00Europe/LondonOrgan-on-a-Chip World Congress and 3D-PrintingOrgan-on-a-Chip World Congress and 3D-Printing in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com